| Literature DB >> 21108954 |
S Hossein Fatemi1, Timothy D Folsom.
Abstract
Fragile X mental retardation protein (FMRP) is highly enriched in neurons and binds to approximately 4% of mRNAs in mammalian brain. Its loss is a hallmark of fragile X syndrome (FXS), the most common form of mental retardation. In this review we discuss the mutation in the fragile X mental retardation-1 gene (FMR1), that leads to FXS, the role FMRP plays in neuronal cells, experiments from our own laboratory that demonstrate reductions of FMRP in additional psychiatric disorders (autism, schizophrenia, bipolar disorder, and major depressive disorder), and potential therapies to ameliorate the loss of FMRP. This article is part of a Special Issue entitled 'Trends in neuropharmacology: in memory of Erminio Costa'.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21108954 PMCID: PMC3078953 DOI: 10.1016/j.neuropharm.2010.11.011
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250